In 2010, Graeser et al. demonstrated its predictive value in breast cancer patients undergoing neoadjuvant chemotherapy, showing that tumours with a complete pathological response had lower RAD51 scores compared to non-responders (median RAD51 score: 2.6% vs 44%, p = 0.028) [70]. Here, RAD51 is linked to breast cancer.